Related Editorial Big pharma and life science companies are making big news these days. The drug-development space is seeing strong investor interest as these companies make breakthrough advancements that address vast unmet medical needs. Strategic M&A moves are adding spice to the gumbo for investors as pioneering research remains focused on providing life-changing treatments for … Continue reading “NetworkNewsAudio – Cybin Inc. (NEO: CYBN) At the Forefront of Psychedelic Therapeutic Protocols, Development”
Cybin (NEO: CYBN), a leading Toronto-based biotech and life sciences company focused on psychedelic pharmaceutical therapies, today made its debut on the global public markets and is now trading on the NEO Exchange under the symbol “CYBN.” The company, which focuses on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols, recently closed … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) Goes Public on Canada’s Next-Gen Stock Exchange”
CYBIN (formerly Clarmin Explorations Inc.), a life sciences company initially focused on psychedelic pharmaceutical therapies, on Thursday announced it has completed its previously disclosed reverse takeover of Clarmin Explorations Inc. per the terms of an amalgamation agreement dated June 26, 2020, as amended on October 21, 2020. The agreement was among Cybin Corp., Clarmin and … Continue reading “NetworkNewsBreaks – CYBIN Inc. Completes Reverse Takeover Transaction”
Cybin Corp., a Canada-based, life-science company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://nnw.fm/wPyaa). Drysdale, named an Ernst and Young Entrepreneur of the Year in 2012, brings more than three decades of experience in the health-care sector and will continue to grow the company’s IP portfolio. “With his myriad … Continue reading “NetworkNewsBreaks – Cybin Corp. Paves Path to Profitability with Health-Care Veteran at the Helm”
Backed by an anonymous donor, Berkeley launches a center for psychedelic science and public education Berkley follows examples of other notable universities such as Johns Hopkins in Maryland, Imperial College in London, and Canadian Centre for Psychedelic Science As an innovative company focusing on psilocybin, CYBIN is set to capitalize on growing academic, commercial attention … Continue reading “CYBIN Corp. Set to Benefit from Growing Research, Interest in Psychedelics”
Cybin appoints health-care expert Doug Drysdale as new CEO. Company confident that his extensive health-care sector background, international company management skills will strengthen Cybin partnerships. New CEO says business model, talented management team positions company to examine new psychedelic-based therapies, delivery systems. Cybin Corp.,a life sciences company advancing psychedelic pharmaceuticals, recently announced the appointment of … Continue reading “Cybin Corp. Appoints New CEO with Impressive Health-Care Expertise”
Related Editorial Compelling evidence of the therapeutic benefits of psychedelic drugs appears in multiple scientific studies. Several clinical trials are underway in the United States and worldwide to investigate the therapeutic effects of psilocybin, the active component in the fungi known colloquially as “magic mushrooms.” There is new hope for treating such debilitating disorders as … Continue reading “NetworkNewsAudio – Cybin Corp. Targeting Underserved Mental Illnesses with Drugs Derived from Psychedelics”
Pure Extract Technologies, a private, plant-based extraction company, is positioned for opportunity as interest grows in the psychedelic and functional mushrooms sector. Recent groundbreaking research indicates that psilocybin-assisted psychotherapy may be effective in treating depression, a debilitating disorder that plagues an estimated 300 million people across the United States. According to a recent National Centre … Continue reading “NetworkNewsBreaks – Pure Extract Technologies Inc. Eyes Opportunity as Psilocybin Shows Promise for Treating Depression”
Cybin Corp., a Canada-based, life-science company, is focused on the development of mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products. The company is positioning as countries around the world become increasingly accepting of psilocybin’s use in controlled settings and recent clinical studies unveil its potential in treating mental health disorders and other conditions. A recent article … Continue reading “NetworkNewsBreaks – Cybin Corp. Holds Distinct Strength in Psychedelics Space”
Cybin Corp., a Canada-based, life-science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, recently announced the appointment of Doug Drysdale as the company’s chief executive officer. Well recognized in the pharmaceutical space, Drysdale brings more than three decades of experience and a recognition of psychedelics as a major breakthrough in treating mental health conditions. … Continue reading “NetworkNewsBreaks – Cybin Corp. CEO Eyes Opportunity in Psychedelics Space, Organic IP Expansion”
